Heron Therapeutics (HRTX)
1.7800 +0.0500 (+2.89%) 12:48 ET [NASDAQ]
1.7700 x 405 1.7800 x 294
Realtime by (Cboe BZX)
1.7700 x 405 1.7800 x 294
Realtime 1.7300 unch (unch) 08:53 ET
for Mon, Feb 24th, 2025
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
Cash Flows From Operating Activities | |||||
Net Income | -110,559 | -182,024 | -220,683 | -227,278 | -204,749 |
Depreciation Amortization | 1,499 | 2,355 | 4,257 | 4,401 | -636 |
Accounts receivable | -8,088 | -16,550 | 6,351 | -1,971 | 24,773 |
Accounts payable and accrued liabilities | 15 | -578 | 3,278 | -2,233 | -14,105 |
Other Working Capital | 16,790 | -10,506 | -35,079 | -13,008 | 29,233 |
Other Operating Activity | 41,554 | 60,391 | 38,522 | 55,269 | 40,904 |
Operating Cash Flow | $-58,789 | $-146,912 | $-203,354 | $-184,820 | $-124,580 |
Cash Flows From Investing Activities | |||||
Change In Deposits | 19,527 | -1,726 | 35,719 | 215,768 | -14,629 |
PPE Investments | -1,532 | -1,598 | -2,990 | -6,813 | -7,154 |
Investing Cash Flow | $17,995 | $-3,324 | $32,729 | $208,955 | $-21,783 |
Cash Flows From Financing Activities | |||||
Debt Issued | 24,350 | N/A | 148,963 | 26 | N/A |
Common Stock Issued | 29,756 | 75,059 | 7,065 | 9,076 | 186,424 |
Other Financing Activity | 1 | 0 | 0 | 3 | 1 |
Financing Cash Flow | $54,107 | $75,059 | $156,028 | $9,105 | $186,425 |
Beginning Cash Position | 15,364 | 90,541 | 105,138 | 71,898 | 31,836 |
End Cash Position | 28,677 | 15,364 | 90,541 | 105,138 | 71,898 |
Net Cash Flow | $13,313 | $-75,177 | $-14,597 | $33,240 | $40,062 |
Free Cash Flow | |||||
Operating Cash Flow | -58,789 | -146,912 | -203,354 | -184,820 | -124,580 |
Capital Expenditure | -1,545 | -1,825 | -3,022 | -6,813 | -7,154 |
Free Cash Flow | -60,334 | -148,737 | -206,376 | -191,633 | -131,734 |